{"id":"NCT01374906","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease","officialTitle":"A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11-04","primaryCompletion":"2016-12-21","completion":"2016-12-21","firstPosted":"2011-06-16","resultsPosted":"2018-04-11","lastUpdate":"2018-05-22"},"enrollment":150,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Cushing's Disease"],"interventions":[{"type":"DRUG","name":"pasireotide LAR","otherNames":["SOM230"]},{"type":"DRUG","name":"SOM230 LAR 30 mg","otherNames":[]},{"type":"DRUG","name":"SOM230 LAR 10 mg","otherNames":[]}],"arms":[{"label":"10 mg LAR dose","type":"EXPERIMENTAL"},{"label":"30 mg LAR dose","type":"EXPERIMENTAL"}],"summary":"This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease.","primaryOutcome":{"measure":"Percentage Participants That Attained a mUFC ≤ 1.0 x ULN at Month 7 Regardless of Dose Titration","timeFrame":"Month 7","effectByArm":[{"arm":"10 mg Pasireotide LAR Dose","deltaMin":41.9,"sd":null},{"arm":"30 mg Pasireotide LAR Dose","deltaMin":40.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":82,"countries":["United States","Argentina","Belgium","Brazil","Canada","China","France","Germany","India","Israel","Italy","Japan","Netherlands","Peru","Poland","Russia","Spain","Thailand","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["32385851","31804965","31465533","29032078","27405306"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":74},"commonTop":["Hyperglycaemia","Diarrhoea","Cholelithiasis","Diabetes mellitus","Nausea"]}}